Acura Pharmaceuticals (ACUR) Receiving Somewhat Favorable Media Coverage, Study Shows

News headlines about Acura Pharmaceuticals (NASDAQ:ACUR) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Acura Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 44.6093124022291 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Acura Pharmaceuticals (NASDAQ ACUR) traded down 11.638% during midday trading on Friday, hitting $0.432. The stock had a trading volume of 2,937 shares. The stock has a 50 day moving average of $0.45 and a 200 day moving average of $0.51. Acura Pharmaceuticals has a 12 month low of $0.40 and a 12 month high of $1.60. The stock’s market cap is $8.96 million.

Acura Pharmaceuticals (NASDAQ:ACUR) last posted its quarterly earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The firm had revenue of $0.09 million for the quarter. Acura Pharmaceuticals had a negative return on equity of 1,237.56% and a negative net margin of 2,335.87%. Analysts expect that Acura Pharmaceuticals will post ($0.46) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Acura Pharmaceuticals (ACUR) Receiving Somewhat Favorable Media Coverage, Study Shows” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://transcriptdaily.com/2017/10/08/acura-pharmaceuticals-acur-receiving-somewhat-favorable-media-coverage-study-shows.html.

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.

Insider Buying and Selling by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)

Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply